Patient and disease characteristics
| N | 86 |
| Median age, y (range) | 52 (22-70) |
| Sex | 52 M, 34 F |
| Diagnosis and status at transplantation | |
| AML/MDS | 43 |
| CR1 | 1 |
| Untreated 1st relapse | 10 |
| Remission ≥ CR2 | 5 |
| Refractory | 27 |
| CML | 27 |
| CR1 | 6 |
| Transformed | 21 |
| ALL/lymphoma | 16 |
| Remission ≥ CR2 | 1 |
| Refractory | 15 |
| Median no. prior therapies (range) | 3 (0-8) |
| Median time to transplantation, d (range) | 553 (27-6627) |
| Prior transplantation | 24 |
| Autologous | 16 |
| Allogeneic different donor | 5 |
| Allogeneic same donor | 3 |
| Donor type | |
| 6 of 6 Matched related | 39 |
| 5 of 6 Mismatched related | 7 |
| 6 of 6 Matched unrelated | 40 |
| Stem cell source | |
| Bone marrow | 52 |
| Peripheral blood | 34 |
| CMV Status | |
| Neg/neg | 6 |
| Donor/recipient sex | |
| Donor F/recipient M | 23 |
| Donor F/recipient F | 19 |
| Other | 44 |
| Preparative regimen | |
| Fludarabine/melphalan 180 | 66 |
| Fludarabine/melphalan 140 | 12 |
| Cladribine/melphalan 180 | 8 |
| GVHD prophylaxis | |
| Tacrolimus/methotrexate | 81 |
| Other | 5 |
| N | 86 |
| Median age, y (range) | 52 (22-70) |
| Sex | 52 M, 34 F |
| Diagnosis and status at transplantation | |
| AML/MDS | 43 |
| CR1 | 1 |
| Untreated 1st relapse | 10 |
| Remission ≥ CR2 | 5 |
| Refractory | 27 |
| CML | 27 |
| CR1 | 6 |
| Transformed | 21 |
| ALL/lymphoma | 16 |
| Remission ≥ CR2 | 1 |
| Refractory | 15 |
| Median no. prior therapies (range) | 3 (0-8) |
| Median time to transplantation, d (range) | 553 (27-6627) |
| Prior transplantation | 24 |
| Autologous | 16 |
| Allogeneic different donor | 5 |
| Allogeneic same donor | 3 |
| Donor type | |
| 6 of 6 Matched related | 39 |
| 5 of 6 Mismatched related | 7 |
| 6 of 6 Matched unrelated | 40 |
| Stem cell source | |
| Bone marrow | 52 |
| Peripheral blood | 34 |
| CMV Status | |
| Neg/neg | 6 |
| Donor/recipient sex | |
| Donor F/recipient M | 23 |
| Donor F/recipient F | 19 |
| Other | 44 |
| Preparative regimen | |
| Fludarabine/melphalan 180 | 66 |
| Fludarabine/melphalan 140 | 12 |
| Cladribine/melphalan 180 | 8 |
| GVHD prophylaxis | |
| Tacrolimus/methotrexate | 81 |
| Other | 5 |
y indicates years; M, male; F, female; AML, acute myelogenous leukemia; MDS, myelodysplastic syndromes; CR, chronic phase; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; d, days; CMV, cytomegalovirus; Neg, negative; GVHD, graft-versus-host disease.